Session III:
Clinical Benefit in Patients with Brain Mets

Carey Anders, MD, Co-Chair, Duke University
Tatiana Prowell, MD, Co-Chair, US Food and Drug Administration
Regulatory Challenges With Trials Seeking CNS Efficacy Claims

Shanthi Marur MD
Patricia Keegan MD
Oncology Center of Excellence, FDA
Overview of Challenges

• Efficacy Endpoints
• Eligibility Criteria
• CNS imaging
• Assessment of CNS lesions
• Criteria to assess CNS response
• Study design
Efficacy Endpoints: Challenges

- FDA approval is based on demonstration of clinical benefit (improvement in survival or how a patient feels or functions)
- Demonstration of effects on survival or quality of life require randomized trials – current trials not designed to show such effects
- Effects on tumor in one organ site (e.g., CNS-ORR or CNS-PFS) may not confer clinical benefit in a systemic disease
Eligibility Criteria: Challenges

Considering the efficacy endpoints chosen,
Should patients with CNS metastases be eligible if they
• Are asymptomatic?
• Were locally treated & are stable at study entry?
• Have no neurological dysfunction at study entry?
• Are not receiving corticosteroids at study registration?

Should patients be excluded if they have
• Untreated, symptomatic brain metastases?
• Leptomeningeal involvement?
• Have no assessment for CNS involvement at study entry?
CNS Imaging: Challenges

• Requirement for baseline CNS imaging and documented CNS disease in all patients limits eligibility

• On-treatment evaluations: CNS imaging assessments generally not scheduled at same frequency as extracranial disease assessments –leading to high censoring rates for CNS tumor endpoints.
Assessment of CNS Lesions: Challenges

• Discordance between investigator assessment and Independent Review Committee (IRC) categorizing measurable and non-measurable lesions – higher rate of discrepancy in CNS-ORR between investigator & IRC than for systemic disease.

• Lack of agreed-upon criteria for selection of CNS lesions that have been previously radiated as target lesions (e.g., time from previous irradiation to study entry) – challenges in attribution of treatment effects to study drug
Assessment of Intracranial (IC) Response - Challenges

• Lack of agreement on optimal criteria for IC response
  • RECIST v1.1 supported by RANO ± RANO LM
  • RANO ± RANO LM alone
Study Design: Challenges

• Randomized trials not stratified by
  - presence or absence of brain metastases
  - treated vs untreated brain metastases

• Lack of justification for sample size, prespecified assumptions of treatment effects, prespecified analysis plan and Type I error control.

• High rate of censoring due to systemic progression - what is the clinical benefit of IC ORR in the face of systemic progression?
Further Discussion....

Given that trials must demonstrate the clinical benefit of treatment

• What endpoint(s) would capture clinical benefit of treatment focused on involved site of a systemic disease?

• Who should be included in trials seeking claims for treatment of patients with CNS metastases?

• Appropriate criteria (RECISTv1.1 alone vs RECIST+RANO BM/LM) to characterize clinically important reduction in intracranial metastases.

• Adequately designed trials to support claims attributable to IC ORR independent of effects on systemic disease.